Datasheet for ABIN7233234

# BI-2536

1 Image

Go to Product page

## Overview

| | |
|---|---|
| Quantity: | 5 mg |
| Application: | Inhibition (Inh) |

## Product Details

| | |
|---|---|
| Purpose: | Dual Plk/BRD4 inhibitor, Destabilizes Myc |
| Characteristics: | BI 2536 was originally reported as a potent (IC50's Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM) and selective2 Polo-like kinase inhibitor (IC50's Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM) that caused mitotic arrest and apoptosis induction in various human cancer cell lines. It was later found to be a potent inhibitor (IC50 = 100nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells. BI 2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1. |
| Purity: | >97 % |
| Chemical Name: | 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide |
| Formula: | C28H39N7O3 |
| Solubility: | Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml) |

## Target Details

| | |
|---|---|
| Background: | Apoptosis inducer,Epigenetics,Cell cycle,Myc,Bromodomain,Ubiquitin/Proteasome,Cell death,Cancer,Posttranslational modification,Chromatin |
| Molecular Weight: | 521.67 |
| CAS-No: | 755038-02-9 |

## Application Details

| | |
|---|---|
| Restrictions: | For Research Use only |

## Handling

| | |
|---|---|
| Format: | Powder |
| Storage: | -20 °C |

## Images




**Molecule**

**Image 1.** /

 